Atrium Therapeutics shared its third quarter results, including a $50 million investment and news on its ATR 1072 trial.

Nov 12, 2026, 4:46 PM ETResultsRead the original at SEC EDGAR

Good for RNA

Atrium began its first patient trial for PRKAG2 syndrome, and mouse results showed improved heart signs. Patient results are still pending, but cash is expected to last through 2028.

RNA · Atrium Therapeutics, Inc.

AI read · Good for RNA

The AI's read

The mouse findings give a reason to test ATR 1072, but they do not show that it works in people. Atrium expects its first trial data in the second half of 2027. Its cash gives it time to reach that point. The quarter's $15.3 million in collaboration revenue mainly came from one $15 million BMS milestone, alongside $13.8 million in research costs and $8.2 million in overhead.

BMY · Bristol Myers Squibb

AI read · Neutral

The connection

Atrium reported $15 million in collaboration revenue, mainly from a milestone earned from BMS. The filing reports no new BMS sales or other change to its business outlook.

Get alerts for RNA

Follow Atrium Therapeutics, Inc. (RNA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RNA

Free on the App Store and Google Play, or on the web.